Cellectis gets access to a Japanese firm's iPS cell patents

10/18/2010 | Google

France's Cellectis has secured iPS Academia Japan's patents for induced pluripotent stem cells, according to a report by Kyodo News. The agreement allows Cellectis to use the cells to create treatments and to test the efficacy of drug candidates.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC